News

Bluebird is seeking approval for treating a rare genetic disease, SCD, in patients aged 12 years and above having a history of vaso-occlusive events. A modified form of

Under the deal terms, Lilly will begin a tender offer to purchase all outstanding shares of DICE for an acquisition price of $48 per share in cash, which translates to a total

The NDA was accepted by the regulatory agency for review with a PDUFA target action date set for 17 June 2023. As per the CRL, the regulatory body

With the acquisition, Rosemont will expand its existing portfolio and gain access to the new pipeline of products, providing lifesaving pharmaceuticals across the UK and within overseas markets.

Dubbed Act4Biosimilars Action Plan, the new roadmap has been designed to boost the adoption of global biosimilar products by at least 30% points in more than 30 countries

Vasopressin Injection is a generic equivalent to Par Pharmaceutical’s Vasostrict and is available in a single dose vial of 20 units per 1 mL. Fresenius has invested nearly

EP-104IAR has been designed for meeting the market demand for long-lasting disease relief in many indications and gain benefit from highly localised and longer delivery of corticosteroids. It

The partnership will focus on the production of adenoviral vector. Under the collaboration, Curigin will use the capabilities of Charles River in contract development and manufacturing organisation (CDMO)

Comac founder and CEO Dr Milen Vrabevski and its other shareholders will retain a significant minority stake. The companies have not disclosed the financial terms of the deal.